Who are AZM X mg + AML Y mg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Losartan (+) amlodipine, Telmisartan + Amlodipine, Fimasartan and Amlodipine, Azilsartan Medoxomil and amlodipine, Valsartan + Amlodipine besilate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azm-x-mg-aml-y-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

AZM X mg + AML Y mg — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AZM X mg + AML Y mg (AZM X mg + AML Y mg) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin II receptor blocker + Calcium channel blocker combination. Area: Cardiovascular.

phase 3 Angiotensin II receptor blocker + Calcium channel blocker combination AT1 receptor (azilsartan); L-type calcium channel (amlodipine) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

AZM X mg + AML Y mg (AZM X mg + AML Y mg) — Celltrion. AZM (azilsartan) is an angiotensin II receptor blocker and AML (amlodipine) is a calcium channel blocker; together they reduce blood pressure through complementary vasodilatory pathways.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AZM X mg + AML Y mg TARGET	AZM X mg + AML Y mg	Celltrion	phase 3	Angiotensin II receptor blocker + Calcium channel blocker combination	AT1 receptor (azilsartan); L-type calcium channel (amlodipine)
Losartan (+) amlodipine	Losartan (+) amlodipine	Organon and Co	marketed	Angiotensin II receptor blocker + calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
Telmisartan + Amlodipine	Telmisartan + Amlodipine	Daewon Pharmaceutical Co., Ltd.	marketed	Angiotensin II receptor blocker + Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
Fimasartan and Amlodipine	Fimasartan and Amlodipine	Boryung Pharmaceutical Co., Ltd	phase 3	Angiotensin II receptor blocker + Calcium channel blocker combination	AT1 receptor (fimasartan); L-type calcium channel (amlodipine)
Azilsartan Medoxomil and amlodipine	Azilsartan Medoxomil and amlodipine	Takeda	phase 3	Angiotensin II receptor blocker + calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
Valsartan + Amlodipine besilate	Valsartan + Amlodipine besilate	Novartis	phase 3	Angiotensin II receptor blocker + Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin II receptor blocker + Calcium channel blocker combination class)

Boryung Pharmaceutical Co., Ltd · 1 drug in this class
Celltrion · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZM X mg + AML Y mg — Competitive Intelligence Brief. https://druglandscape.com/ci/azm-x-mg-aml-y-mg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab